CoChat

Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis

Colao, Annamaria, Vitale, Giovanni, Cappabianca, Paolo, Briganti, Francesco, Ciccarelli, Antonio, De Rosa, Michele, Zarrilli, Stefano, Lombardi, Gaetano · 2004 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17-70 yr) and 10 with microprolactinoma (age 18-53 yr). Fifty-one age-matched men served as controls for semen analysis. At study entry, of the 41 patients with macroprolactinoma, 17 (41.4%) had visual field defects, 14 (34.1%) had headache, eight (19.5%) had galactorrhea, 22 (53.6%) had hypopituitarism apart from hypogonadism, and 30 (73.2%) had low testosterone levels; of the 10 patients with microprolactinoma, none had visual field defects, galactorrhea, or hypopituitarism apart from hypogonadism, two had headache (20%), and five had low testosterone levels (50%; P = 0.3). After 24 months of therapy, 1) PRL levels normalized in 31 patients with macro- (75.6%) and in eight with microprolactinoma (80%; P = 0.9), and galactorrhea disappeared in all patients; 2) maximal tumor diameter reduced by 73.7 +/- 22.6% in macro- and 72.8 +/- 28.3% in microprolactinomas (P = 0.91), and 15 macro- (30%) and seven microprolactinomas (46.7%; P = 0.37) disappeared; 3) visual field defects disappeared in 15 (75%) patients with macroprolactinoma, and headache disappeared in 15 (83%) patients with macro- and in one with microprolactinoma (50%); 4) GH secretion recovered in 62.5% and ACTH secretion in 60% of patients; 5) testosterone levels normalized in 25 patients with macro- (60.9%) and six with microprolactinoma (60%) after 6 months, and 20 patients required testosterone or gonadotropin replacement (in 14 or six patients, respectively); and 6) sperm volume and count normalized in all patients who normalized testosterone levels, whereas motility normalized in more than 80%. Cabergoline therapy was well tolerated; only 4.5% of patients had side effects at high doses. These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2003-030979

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 260

Metadata

Authors
Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G.
Affiliations
Federico II University Hospital (IT)
Corresponding author
Colao, Annamaria
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-04
Volume
89
Issue
4
Pages
1704-1711
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2091047975
Cited by
256
References
28
Citations by year
2026: 15 · 2025: 11 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 13 · 2020: 7 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 8 · 2014: 10 · 2013: 16 · 2012: 11
FWCI
5.58
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
cabergoline, prolactinoma, macroprolactinoma, microprolactinoma, prolactin normalization, tumor shrinkage, pituitary function recovery, hypogonadism, testosterone, semen quality, sperm count, sperm motility, visual field defects, headache, galactorrhea, hypopituitarism, dopamine agonists
MeSH terms
Cabergoline, Adolescent, Adult, Aged, Drug Administration Schedule, Ergolines, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Gland, Pituitary Neoplasms, Prolactin, Semen, Prolactinoma, Treatment Outcome, Dopamine Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis. https://app.cochat.ai/papers/10.1210/jc.2003-030979
The paper
Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G. (2004). Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-030979

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.